Professor Jenkins’s research falls within the “Biomarkers and Genes” theme of the Medical School.
His research group investigate the molecular basis of cancer in the gastrointestinal tract, particularly the pre-malignant condition; Barrett’s Oesophagus. Group aims are to develop early detection systems for cancer. His blood based cancer detection approach (based on Pig A gene mutations in red blood cells) recently received a lot of media interest. His group investigate DNA damage levels in Barrett’s patients and NF-kB signalling induced in oesophageal tissues. The research is aimed at better understanding early carcinogenesis and to identify diagnostic markers for clinical utility. Professor Jenkins also collaborates with others in the areas of colorectal cancer biology and pancreatic cancer.
He is also an internationally recognised researcher in the field of Genetic Toxicology (DNA damage), being at the forefront of research efforts to improve in vitro (cell-based) assessment of genotoxic risks from chemical exposure. Current work centres on mechanistic studies of genotoxic thresholds, 3-D tissue models for genotoxicity and coupling genotoxic assessment with disruption of other cell biological processes (cell cycle, cell signalling, cell morphology).
Professor Jenkins was appointed to the UK Government’s Committee on Mutagenicity (COM) in 2009, was appointed a “Research Leader” by Health and Care Research Wales in 2012 and was appointed Senior Editor of Mutagenesis in 2016. He has received over £3million in grant income, written over 70 peer-reviewed papers and edited a book on the toxicology of Bile acids. Professor Jenkins is the head of research at the Medical School. He has an Honorary position at Abertawe Bro Morgannwg University (ABMU) Health Board.